Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
API
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Agrastat
2. L 700,462
3. L 700462
4. L-700,462
5. L-700462
6. L700,462
7. Mk 383
8. Mk-383
9. N-(butylsulfonyl)-o-(4-(4-piperidyl)butyl)-l-tyrosine
10. Tirofiban
11. Tirofiban Hydrochloride
12. Tirofiban Hydrochloride Monohydrate
1. Tirofiban Hydrochloride
2. 142373-60-2
3. Tirofiban Hcl
4. Tirofiban (hydrochloride)
5. Tirofiban Hydrochloride Anhydrous
6. Ike1p4x57j
7. (s)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic Acid Hydrochloride
8. Mk 383
9. L 700462
10. 142373-60-2 (hcl)
11. L-tyrosine, N-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, Monohydrochloride
12. Tirofibanhydrochloridemonohydrate
13. N-(butylsulfonyl)-o-[4-(4-piperidinyl)butyl]-l-tyrosine Hydrochloride
14. L-700462
15. Mk-383
16. Unii-ike1p4x57j
17. N-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-l-tyrosine Monohydrochloride
18. Chembl1704
19. Schembl41327
20. Dtxsid70931418
21. 2-(butylsulfonylamino)-3-[4-[4-(4-piperidinyl)butoxy]phenyl]propanoic Acid Hydrochloride
22. Amy23379
23. Ex-a2875
24. Hy-17369a
25. Mfcd00868210
26. Akos025311245
27. Tirofiban Hydrochloride [who-dd]
28. Cs-0009551
29. T3640
30. Tirofiban Hydrochloride Anhydrous [mi]
31. 915t405
32. Q27280770
33. (s)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoicacidhydrochloride
34. L-tyrosine, N-(butylsulfonyl)-o-(4-(4-piperidinyl)butyl)-, Hydrochloride (1:1)
35. N-(butane-1-sulfonyl)-o-[4-(piperidin-4-yl)butyl]tyrosine--hydrogen Chloride (1/1)
36. (2s)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic Acid;hydrochloride
Molecular Weight | 477.1 g/mol |
---|---|
Molecular Formula | C22H37ClN2O5S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 14 |
Exact Mass | 476.2111712 g/mol |
Monoisotopic Mass | 476.2111712 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 579 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Fibrinolytic Agents
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-05
Pay. Date : 2013-09-12
DMF Number : 23173
Submission : 2009-10-07
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-04-12
Pay. Date : 2018-05-25
DMF Number : 32701
Submission : 2018-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26942
Submission : 2013-03-14
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-05
Pay. Date : 2013-09-12
DMF Number : 23173
Submission : 2009-10-07
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-04-12
Pay. Date : 2018-05-25
DMF Number : 32701
Submission : 2018-04-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26942
Submission : 2013-03-14
Status : Inactive
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : ALP Pharm began to manufacture some APIs in the partner's facilities in 2007. Some of our APIs have been approved by EDQM and US FDA. Our professional regulatory compliance experts...
About the Company : Eagle Chemical was founded in the year 1978 by Gautam Shah a man with an enterprising zeal & a vision to make a mark in the nascent pharmaceutical raw material manufacturing sector...
About the Company : A globally renowned manufacturer of Small Volume Parenterals (SVPs), Gland Pharma was founded in 1978 at Hyderabad by a visionary, PVN Raju, who has always thought far ahead of his...
About the Company : Guangzhou Topwork Chemical Co., Ltd. Specializes in manufacturing corticosteroid and relative intermediates. We provide high quality products and excellent service to our clients a...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...
About the Company : Established in 2002, Tecoland represents selected cGMP manufacturers with proven capabilities in organic synthesis, fermentation production as well as process and method developmen...
About the Company : Xi'an Wanlong Pharmaceutical Co., Ltd was founded in 1995 and it is comprehensive modern pharmaceutical enterprise which mainly produces formulations, API and intermediates, GMP & ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tirofiban Hydrochloride-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nexus Pharmaceuticals Inc. Receives FDA Approval for Tirofiban Hydrochloride Injection
Details : Tirofiban hydrochloride is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor. It is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome.
Brand Name : Tirofiban Hydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2023
Details:
Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia.
Lead Product(s): Tirofiban,Clopidogrel,Aspirin
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Aggrastat
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Lead Product(s) : Tirofiban,Clopidogrel,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 ...
Details : Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves...
Brand Name : Aggrastat
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 24, 2020
Details:
The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.
Lead Product(s): Tirofiban,Prasugrel
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Aggrastat
Study Phase: Phase IVProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Lead Product(s) : Tirofiban,Prasugrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT
Details : The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of prima...
Brand Name : Aggrastat
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2020
Details:
The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Lead Product(s): Tirofiban
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Hong Kong Teson Pharma
Deal Size: $3.5 million Upfront Cash: $3.0 million
Deal Type: Agreement March 10, 2020
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Hong Kong Teson Pharma
Deal Size : $3.5 million
Deal Type : Agreement
Correvio Partners with Hong Kong Teson Pharma Limited
Details : The investment vehicle, which LSP claims is the largest of its type in Europe, is bigger than the VC shop’s three previous life science funds combined.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $3.0 million
March 10, 2020
4-(4-chlorobutyl)pyridine hydrochloride
CAS Number : 149463-65-0
End Use API : Tirofiban
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
L-N-Butylsulfonyl-P- Hydroxyphenylalanine
CAS Number : 149490-60-8
End Use API : Tirofiban
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Aggrastet 0,05 mg/ml
Dosage Form : INF
Dosage Strength : 0.05mg/ml
Packaging : 250X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Aggrastat
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.
Regulatory Info :
Registration Country : France
Brand Name :
Dosage Form : Solution for Infusion
Dosage Strength : 50MCG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : France
Regulatory Info : RX
Registration Country : USA
Brand Name : TIROFIBAN HYDROCHLORIDE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)
Packaging :
Approval Date : 2023-05-01
Application Number : 216379
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Prescription
Registration Country : Canada
TIROFIBAN (TIROFIBAN HYDROCHLORIDE)
Brand Name : AGGRASTAT
Dosage Form : SOLUTION
Dosage Strength : 12.5MG/250ML
Packaging : 250ML
Approval Date :
Application Number : 2240706
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Solution for Injection
Dosage Strength : 12.5MG/50ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Regulatory Info : RX
Registration Country : USA
Brand Name : TIROFIBAN HYDROCHLORIDE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)
Packaging :
Approval Date : 2021-04-08
Application Number : 206888
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Australia
Brand Name : Tirofiban Juno
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : DISCN
Registration Country : USA
Brand Name : AGGRASTAT
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)
Packaging :
Approval Date : 1998-05-14
Application Number : 20912
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : AGGRASTAT
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)
Packaging :
Approval Date : 2002-05-17
Application Number : 20913
Regulatory Info : RX
Registration Country : USA
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Brand Name : Sodium Citrate Dihydrate Multi-Compendial
Application : Controlled & Modified Release
Excipient Details : A & C's Sodium Citrate Dihydrate multi-compendial is a trisodium salt of citric acid.
Pharmacopoeia Ref : Multi-compendial
Technical Specs : Not Available
Ingredient(s) : Sodium Citrate Dihydrate Excipient
Brand Name : Sodium Citrate Dihydrate USP-NF
Application : Controlled & Modified Release
Excipient Details : A & C's Sodium Citrate Dihydrate USP-NF is a trisodium salt of citric acid.
Pharmacopoeia Ref : USP/NF
Technical Specs : Not Available
Ingredient(s) : Sodium Citrate Dihydrate Excipient
Global Sales Information
Dosage Form : Tirofiban 12.5Mg 50Ml 1 Units Pa...
Dosage Strength : 1 vial EV 50 ml 250 mcg/ml
Price Per Pack (Euro) : 262.9
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Market Place
Reply
19 Jul 2022
Reply
27 Nov 2020
Reply
17 Sep 2018
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.64
Tirofiban Hydrochloride Hydrate
CAS Number : 150915-40-5
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.21
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.10
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.11
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.13
CAS Number : 2250243-43-5
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.02
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.25
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.03
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.04
CAS Number :
Quantity Per Vial :
Sale Unit :
Price :
Details : In stock
Monograph :
Storage :
Code/Batch No : T0101.05
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?